Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
August 6, 2024
Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia
July 31, 2024
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
July 23, 2024
Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024
July 16, 2024
Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
June 24, 2024
Beyond Air® Appoints David Webster as Chief Commercial Officer
June 13, 2024
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
June 3, 2024
Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast
May 23, 2024
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
May 1, 2024
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
March 20, 2024

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe